Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva MS Success Helps Stock In Down Month: Biogen, Chiron Tumble

Executive Summary

Teva's smooth performance in the multiple sclerosis market is shoring up the company in a difficult environment for biopharmaceutical stocks.

You may also be interested in...



Teva/BTG Tev-Tropin

Teva/Bio-Technology General Corp.'s human growth hormone Tev-Tropin will be introduced "at the earliest opportunity" following U.S. appellate court decision to vacate June 2002 preliminary injunction against U.S. marketing of the product, BTG says. The injunction was requested by Novo. The company's process patent case arose out of previous process patent litigation between BTG and Genentech, which was resolved when BTG received FDA approval to change its manufacturing process (1"The Pink Sheet" May 8, 2000, p. 22). Novo claimed BTG's manufacturing change violated Novo patents. Teva holds marketing rights to Tev-Tropin and has ultimate decision on a launch date, BTG says...

Teva/BTG Tev-Tropin

Teva/Bio-Technology General Corp.'s human growth hormone Tev-Tropin will be introduced "at the earliest opportunity" following U.S. appellate court decision to vacate June 2002 preliminary injunction against U.S. marketing of the product, BTG says. The injunction was requested by Novo. The company's process patent case arose out of previous process patent litigation between BTG and Genentech, which was resolved when BTG received FDA approval to change its manufacturing process (1"The Pink Sheet" May 8, 2000, p. 22). Novo claimed BTG's manufacturing change violated Novo patents. Teva holds marketing rights to Tev-Tropin and has ultimate decision on a launch date, BTG says...

Teva Copaxone Nears U.K. Approval, But NICE To Refuse MS Drug Payment

Teva is expecting U.K. licensure of its multiple sclerosis drug Copaxone (glatiramer) in July for reduction in frequency of relapse in relapsing/remitting MS, the company indicated.

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel